[1] Schapira AH. Mitochondrial disease[J]. Lancet, 2006, 368:70-82. [2] Duran J, Martinez A, Adler E. Cardiovascular manifestations of mitochondrial disease[J]. Biology (Basel), 2019, 8:34. [3] El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome:clinical manifestations, pathogenesis, and treatment options[J]. Mol Genet Metab, 2015, 116:4-12. [4] Messinis DE, Melas IN, Hur J, Varshney N, Alexopoulos LG, Bai JPF. Translational systems pharmacology-based predictive assessment of drug-induced cardiomyopathy[J]. CPT Pharmacometrics Syst Pharmacol, 2018, 7:166-174. [5] Finsterer J, Zarrouk-Mahjoub S. Arrhythmias in MELAS syndrome[J]. Mol Genet Metab Rep, 2016, 7:54. [6] Sproule DM, Kaufmann P, Engelstad K, Starc TJ, Hordof AJ, De Vivo DC. Wolff-Parkinson-White syndrome in patients with MELAS[J]. Arch Neurol, 2007, 64:1625-1627. [7] Chen JG, Wu M, Zhang X. Mitochondrial encephalomyopathy with lactic acidosis and stroke-like attack syndrome with arrhythmia:a case report[J]. Zhongguo Xiao Er Ji Jiu Yi Xue, 2016, 23:213-216.[陈俊国, 吴鸣, 张旭. 线粒体脑肌病伴乳酸酸中毒及卒中样发作综合征并发心律失常一例[J]. 中国小儿急救医学, 2016, 23:213-216.] [8] Xie HL, Zhang LL, Yu XE, Sha CP, Shi YG, Chen L, Song B, Zhang J. Clinicopathological analysis of 5 cases of mitochondrial encephalomyopathy with hyperlactic acidemia and stroke-like attack syndrome with preexcitation syndrome[J]. Lin Chuang Yu Shi Yan Bing Li Xue Za Zhi, 2019, 35:1099-1101.[谢后林, 张亮亮, 喻绪恩, 沙从波, 石永光, 陈林, 宋彬, 张杰. 伴预激综合征的线粒体脑肌病伴高乳酸血症和卒中样发作综合征5 例临床病理分析[J]. 临床与实验病理学杂志, 2019, 35:1099-1101.] [9] Rare Diseases Branch of Beijing Medical Association; Neuromuscular Group, Neurology Branch, Beijing Medical Association; Chinese Cooperative Group on Mitochondrial Diseases. Chinese expert consensus on diagnosis and treatment of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes[J]. Zhonghua Shen Jing Ke Za Zhi, 2020, 53:171-178.[北京医学会罕见病分会, 北京医学会神经内科分会神经肌肉病学组, 中国线粒体病协作组. 中国线粒体脑肌病伴高乳酸血症和卒中样发作的诊治专家共识[J]. 中华神经科杂志, 2020, 53:171-178.] [10] Brambilla A, Favilli S, Olivotto I, Calabri GB, Porcedda G, De Simone L, Procopio E, Pasquini E, Donati MA. Clinical profile and outcome of cardiac involvement in MELAS syndrome[J]. Int J Cardiol, 2019, 276:14-19. [11] Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults:an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. J Am Soc Echocardiogr, 2015, 28:1-39.e14. [12] Woroniecki RP, Kahnauth A, Panesar LE, Supe-Markovina K. Left ventricular hypertrophy in pediatric hypertension:a mini review[J]. Front Pediatr, 2017, 5:101. [13] Marin-Garcia J, Goldenthal MJ. Mitochondrial DNA defects in cardiomyopathy[J]. Cardiovasc Pathol, 1998, 7:205-213. [14] Tsang SH, Aycinena ARP, Sharma T. Mitochondrial disorder:Kearns-Sayre syndrome[J]. Adv Exp Med Biol, 2018, 1085:161-162. [15] Lev D, Nissenkorn A, Leshinsky-Silver E, Sadeh M, Zeharia A, Garty BZ, Blieden L, Barash V, Lerman-Sagie T. Clinical presentations of mitochondrial cardiomyopathies[J]. Pediatr Cardiol, 2004, 25:443-450. [16] Majamaa-Voltti K, Peuhkurinen K, Kortelainen ML, Hassinen IE, Majamaa K. Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A > G[J]. BMC Cardiovasc Disord, 2002, 2:12. [17] Stalder N, Yarol N, Tozzi P, Rotman S, Morris M, Fellmann F, Schwitter J, Hullin R. Mitochondrial A3243G mutation with manifestation of acute dilated cardiomyopathy[J]. Circ Heart Fail, 2012, 5:e1-3. [18] Okajima Y, Tanabe Y, Takayanagi M, Aotsuka H. A follow up study of myocardial involvement in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)[J]. Heart, 1998, 80:292-295. [19] Vydt TC, de Coo RF, Soliman OI, Ten Cate FJ, van Geuns RJ, Vletter WB, Schoonderwoerd K, van den Bosch BJ, Smeets HJ, Geleijnse ML. Cardiac involvement in adults with m.3243A > G MELAS gene mutation[J]. Am J Cardiol, 2007, 99:264-269. [20] Holmgren D, Wåhlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings[J]. Eur Heart J, 2003, 24:280-288. [21] Malfatti E, Laforêt P, Jardel C, Stojkovic T, Behin A, Eymard B, Lombès A, Benmalek A, Bécane HM, Berber N, Meune C, Duboc D, Wahbi K. High risk of severe cardiac adverse events in patients with mitochondrial m. 3243A > G mutation[J]. Neurology, 2013, 80:100-105. [22] Bohles H, Sewell AC. Metabolic cardiomyopathy[M]. Stuttgart:Medpharm Scientific Publishers, 2004:67-84. [23] Sproule DM, Dyme J, Coku J, de Vinck D, Rosenzweig E, Chung WK, De Vivo DC. Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA(Leu) gene (m.3243A > G)[J]. J Inherit Metab Dis, 2008, 31 Suppl 3:497-503. [24] El-Hattab AW, Hsu JW, Emrick LT, Wong LJ, Craigen WJ, Jahoor F, Scaglia F. Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation[J]. Mol Genet Metab, 2012, 105:607-614. [25] El-Hattab AW, Emrick LT, Craigen WJ, Scaglia F. Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders[J]. Mol Genet Metab, 2012, 107:247-252. [26] El-Hattab AW, Emrick LT, Chanprasert S, Craigen WJ, Scaglia F. Mitochondria:role of citrulline and arginine supplementation in MELAS syndrome[J]. Int J Biochem Cell Biol, 2014, 48:85-91. [27] Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, Fujimoto S, Matsuishi T. L-arginine improves the symptoms of strokelike episodes in MELAS[J]. Neurology, 2005, 64:710-712. [28] Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Katayama K, Matsuishi T. MELAS and L-arginine therapy[J]. Mitochondrion, 2007, 7:133-139. [29] Thomas T, Craigen WJ, Moore R, Czosek R, Jefferies JL. Arrhythmia as a cardiac manifestation in MELAS syndrome[J]. Mol Genet Metab Rep, 2015, 4:9-10. [30] Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome[J]. N Engl J Med, 2001, 344:1823-1831. [31] Finsterer J, Zarrouk-Mahjoub S. The heart in m. 3243A > G carriers[J]. Herz, 2020, 45:356-361. [32] Wortmann SB, Rodenburg RJ, Backx AP, Schmitt E, Smeitink JA, Morava E. Early cardiac involvement in children carrying the A3243G mtDNA mutation[J]. Acta Paediatr, 2007, 96:450-451. [33] Santorelli FM, Tessa A, D'amati G, Casali C. The emerging concept of mitochondrial cardiomyopathies[J]. Am Heart J, 2001, 141:E1. [34] Mao CG, Nie NN, Guo XQ, Xu M, Yang YL, Li ZP. Mitochondrial diseases with the main manifestations of cardiomyopathy and respiratory muscle damage[J]. Zhonghua Shi Yong Er Ke Lin Chuang Za Zhi, 2016, 31:613-615.[毛成刚, 聂娜娜, 郭兴青, 徐敏, 杨艳玲, 李自普. 以心肌病和呼吸肌受累为主要表现的线粒体病[J]. 中华实用儿科临床杂志, 2016, 31:613-615.] [35] Limongelli G, Tome-Esteban M, Dejthevaporn C, Rahman S, Hanna MG, Elliott PM. Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease[J]. Eur J Heart Fail, 2010, 12:114-121. [36] Dominic EA, Ramezani A, Anker SD, Verma M, Mehta N, Rao M. Mitochondrial cytopathies and cardiovascular disease[J]. Heart, 2014, 100:611-618. [37] Fassone E, Taanman JW, Hargreaves IP, Sebire NJ, Cleary MA, Burch M, Rahman S. Mutations in the mitochondrial complex Ⅰ assembly factor NDUFAF1 cause fatal infantile hypertrophic cardiomyopathy[J]. J Med Genet, 2011, 48:691-697. |